- Nektar Therapeutics (NKTR) +9.2% AH after a long trading halt, as an FDA advisory panel recommended against requiring cardiovascular outcome trials for a certain class of drugs - including NKTR's Movantik - in the treatment of constipation caused by opioid medicines (earlier).
- The drug treatment, being developed by NKTR partner AstraZeneca (AZN), also is being reviewed by health agencies in the European Union and Canada.
- The FDA is expected to make a decision on Movantik by Sept. 16.
From other sites
at CNBC.com (Jun 12, 2014)
at CNBC.com (Sep 27, 2013)
at CNBC.com (Oct 4, 2011)
at CNBC.com (May 16, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs